Actualités de Ballerup, Denmark

27.07.2017 – 15:04
LEO Pharma
LEO Pharma Ranks Second in Global Clinical Trials Transparency Audit
Ballerup, Denmark and Hurley, England (ots/PRNewswire) - New top 50 list ranks LEO Pharma in second position, leading the global pharma industry in commitments to increase access to clinical trials information (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The AllTrials audit on clinical trial transparency findings has been published ranking LEO Pharma as leaders in the industry. LEO Pharma is ranked at number ...
plus
20.07.2017 – 09:01
LEO Pharma
LEO Pharma Receives Marketing Authorisation for Kyntheum® (Brodalumab), a New Biologic for the Treatment of Moderate-to-Severe Plaque Psoriasis in the European Union
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma today announced that the European Commission has granted marketing authorisation for Kyntheum® (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy.[1] ...
plus
15.06.2017 – 07:01
LEO Pharma
LEO Pharma Starts Phase 3 Clinical Study for Tralokinumab in Atopic Dermatitis
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma today announced that the first patients have been dosed in a phase 3 clinical study of tralokinumab. Tralokinumab is an investigational human monoclonal antibody that specifically targets the cytokine IL-13[1], which plays an important role in the development of moderate-to-severe atopic dermatitis[2]. Tralokinumab is not ...
plus
22.05.2017 – 08:01
LEO Pharma
Brodalumab, a Novel Biologic for People with Moderate-to-Severe Psoriasis, Receives Positive Opinion from European CHMP
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
plus
19.05.2017 – 18:06
LEO Pharma
Brodalumab, a Novel Biologic for People with Moderate-to-Severe Psoriasis, Receives Positive Opinion from European CHMP
Ballerup, Denmark (ots/PRNewswire) - Opinion from CHMP: "On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product [brodalumab], intended for the treatment of psoriasis[...]The benefits with ...
plus
03.03.2017 – 16:01
LEO Pharma
LEO Pharma Announces Positive Results From Phase 2b Clinical Study for Tralokinumab in Atopic Dermatitis
Ballerup, Denmark and Orlando, Florida (ots/PRNewswire) - LEO Pharma today announced positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema. Tralokinumab is an investigational ...
plus
01.07.2016 – 08:19
LEO Pharma
LEO Pharma Enters Biologics Through Strategic Partnership With AstraZeneca
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma is a significant step closer to realising its vision of becoming the preferred dermatology care partner following a strategic partnership with AstraZeneca announced today. (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The partnership covers potential new medicines for atopic dermatitis and psoriasis, two of ...
plus
21.03.2016 – 09:01
LEO Pharma
LEO Pharma Receives Scientific Approval of Enstilar® for the Treatment of Psoriasis in EU
Ballerup, Denmark (ots/PRNewswire) - The marketing approval of Enstilar® would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU. LEO Pharma today announced that it received scientific approval of Enstilar® (calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) for the treatment of psoriasis ...
plus
07.03.2016 – 09:01
LEO Pharma
New Preclinical Data for Calcipotriol/betamethasone dipropionate (0,005%/0,05%) Foam Presented at American Academy of Dermatology Congress
Ballerup, Denmark (ots/PRNewswire) - Data presented in a Late Breaking Science session at the 74th Annual Meeting of the American Academy of Dermatology (AAD) in Washington, D.C. demonstrate that calcipotriol/betamethasone dipropionate 50 micrograms/g / 0,5 mg/g) foam formulation is a stable supersaturated solution ...
plus
11.11.2015 – 12:03
LEO Pharma
LEO Pharma to Acquire Global Dermatology Portfolio from Astellas
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, and Japanese pharmaceutical company Astellas Pharma Inc. today announced that they have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma for EUR 675 million. (Logo: ...
plus
06.01.2015 – 06:02
LEO Pharma
LEO Pharma Announces US Regulatory Submission of the First Aerosol Foam for Psoriasis
Ballerup, Denmark (ots/PRNewswire) - - Not Intended for US Media LEO Pharma announced it has submitted a New Drug Application to the US Food and Drug Administration (FDA) for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The novel aerosol foam ...
plus
04.09.2014 – 08:01
LEO Pharma
New Data Presented at WCCS Confirm High Long-term Efficacy of Picato® in Patients with Actinic Keratosis
Ballerup, Denmark (ots/PRNewswire) - Not for US media The digital press release with multimedia content can be accessed here: http://www.multivu.com/players/uk/7276254-WCCS-Picato-actinickeratosis New data from the international FIELD Study Repeat presented today at the 15th World Congress of Cancers of the Skin ...
plus
21.03.2013 – 00:23
LEO Pharma
Article Published in JAMA Dermatology Shows Long-term Effectiveness of Ingenol Mebutate in Treating Actinic Keratosis
Ballerup, Denmark (ots/PRNewswire) - Two-three day treatment provides clinically relevant, sustained clearance of AK after 12 months An analysis of long-term clearance rates of actinic keratosis (AK) lesions after treatment with ingenol mebutate (Picato(R)) gel is today published in the Journal of the American ...
plus
18.03.2013 – 13:03
Virobay, Inc. and LEO Pharma A/S
Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis
Menlo Park, California And Ballerup, Denmark (ots/PRNewswire) - Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S ...
plus
19.11.2012 – 11:45
LEO Pharma
Picato® Gel Receives EU Marketing Authorisation for Treatment of Actinic Keratosis
Ballerup, Denmark (ots/PRNewswire) - Today LEO Pharma announced that the European Commission (EC) has granted marketing authorisation for Picato(R) (ingenol mebutate) gel as a treatment for actinic keratosis in the European Union (EU). Picato(R) gel is a once-daily, two or three day field-directed topical treatment for actinic keratosis, a common skin condition which ...
plus
14.06.2012 – 15:44
LEO Pharma
LEO Pharma Initiates Global Search for New Partners
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma is now actively searching for new global or territorial partners to deliver promising new compounds for its dermatology-focused pipeline. Corporate VP hopes to sign two or more new deals before the end of 2012. (Logo: http://photos.prnewswire.com/prnh/20120614/537969-a ) (Photo: http://photos.prnewswire.com/prnh/20120614/537969-b ) (Photo: ...
plus